Intestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature

BMC Infect Dis. 2015 Oct 28:15:475. doi: 10.1186/s12879-015-1225-0.

Abstract

Background: Multidrug-resistant Escherichia coli and other enteric bacteria producing extended-spectrum β-lactamases (ESBL) have emerged as an important cause of invasive infection. Targeting the primary (intestinal) niche by decolonization may be a valuable approach to decrease the risk of relapsing infections and to reduce transmission of ESBL-producing enteric pathogens.

Methods: In a retrospective observational study we evaluated the efficacy of intestinal decolonization treatment using orally administered colistin or other non-absorbable agents given for 2 to 4 weeks in adult patients with previous relapsing infection and persistent intestinal colonization with ESBL-positive Enterobacteriaceae (ESBL-E). Eradication success was defined as negative rectal swab or stool culture at the end of treatment and at follow up-2 weeks after treatment discontinuation.

Results: First-line decolonization treatment led to eradication of ESBL-E in 19/45 patients (42%, 7/18 low-dose [4 × 1 million units] colistin, 3/12 high-dose [4 × 2 million units] colistin, 9/15 rifaximin [2 × 400 mg]), and secondary/salvage treatment was successful in 8/13 patients (62 %, 20 treatment episodes). Late follow-up showed that 7/13 patients (54%) with successful initial or salvage decolonization became recolonized within 3 months after post-treatment assessment while all eight of the patients failing initial or salvage decolonization treatment with late follow-up remained colonized. A narrative review of the literature confirms the limited efficacy of non-absorbable antibiotics including conventional selective digestive tract decolonization (SDD)-like combination regimens for eradicating multidrug-resistant enteric bacteria from the intestinal tract.

Conclusions: At present, there is no clear evidence of a significant decolonization efficacy using single-drug treatment with oral non-absorbable antibiotics. More effective regimens are needed and a better definition of at risk patients is required for planning meaningful randomized controlled studies in this field.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Colistin / administration & dosage
  • Colistin / therapeutic use*
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / metabolism
  • Enterobacteriaceae / pathogenicity
  • Enterobacteriaceae Infections / microbiology
  • Enterobacteriaceae Infections / prevention & control*
  • Escherichia coli / drug effects
  • Escherichia coli / metabolism
  • Escherichia coli / pathogenicity
  • Female
  • Gastrointestinal Microbiome / drug effects
  • Humans
  • Intestines / drug effects
  • Intestines / microbiology
  • Male
  • Middle Aged
  • Retrospective Studies
  • Rifamycins / therapeutic use
  • Rifaximin
  • Treatment Outcome
  • Young Adult
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Rifamycins
  • beta-Lactamases
  • Rifaximin
  • Colistin